How long after applying AndroGel is it safe to hug my child?

The application site should be washed with soap and water or covered with clothing before any skin-to-skin contact. The FDA Medication Guide for AndroGel does not give a specific time window because washing the site, not waiting, is the recommended method of risk reduction. If you cannot wash before contact, keep the site covered with a shirt.

Can my wife absorb testosterone just by sleeping next to me?

Transfer requires direct skin contact with the application site. Sleeping beside someone does not cause transfer unless the application area (typically shoulders, upper arms, or abdomen) contacts her skin during the night. Wearing a shirt to bed eliminates this route.

My child developed pubic hair. Could AndroGel be the cause?

Yes. This is one of the documented signs of secondary testosterone exposure in children. Seek evaluation from a pediatric endocrinologist promptly. Bring information about the household member's AndroGel use, including dose and application site, to the appointment.

Does the 1.62% gel transfer more than the 1% gel?

A higher concentration applied to the same area delivers a larger testosterone mass per unit volume, which may increase surface residue. The AndroGel 1.62% label carries the same black box warning as the 1% formulation. Precautions are identical regardless of concentration.

What if I apply AndroGel to my abdomen instead of my shoulders? Is transfer less likely?

The abdomen is a labeled application site for AndroGel 1.62%. Transfer risk from the abdomen is real and depends on the same factors as any other site. The key variable is whether clothing covers the area and whether washing occurs before contact, not which body region is used.

Can transfer happen through clothing?

Transfer through fabric is possible but substantially lower than through direct skin contact. Light fabrics that become sweat-dampened provide less of a barrier than dry, thicker clothing. This is one reason the Endocrine Society guideline recommends washing the site rather than relying on clothing alone as the sole precaution.

How do I know if my daughter has been exposed? She has no obvious symptoms yet.

Early exposure may not produce visible signs immediately. If you have had repeated unprotected skin contact with her, speak to her pediatrician about a serum testosterone level and bone age X-ray. These tests can detect hormonal effects before physical signs appear, per AAP precocious puberty guidance.

Is there a testosterone formulation I can use that has zero transfer risk?

Yes. Injectable testosterone (cypionate or enanthate) and subcutaneous testosterone pellets carry no topical transfer risk because the hormone is delivered internally, not applied to the skin surface. Ask your prescriber whether switching formulations is appropriate for your situation.

Do I need to warn my child's school or daycare about this?

If you apply AndroGel in the morning and then engage in physical contact with children in a professional or caregiving setting, the same precautions apply. Covered application sites and hand washing before contact are sufficient in most settings. You do not need to disclose your medication to the school unless a child has already been exposed.

If my partner is also on testosterone for her own medical reasons, does she face the same transfer risks from my gel?

She is still at risk for supraphysiologic testosterone levels from additive exposure. Her prescriber should be aware that she has a potential secondary source of testosterone in the household and should monitor her levels accordingly.

Transfer to Women and Children on AndroGel: Week-by-Week Timeline of What to Expect

By HealthRX Medical Team

Published Jul 14, 2025Updated Jul 14, 2025Last reviewed Jul 14, 2025

Transfer to Women and Children on AndroGel: Week-by-Week Timeline of What to Expect

At a glance

Incidence from trial data: The FDA reviewed multiple pediatric secondary exposure cases between 2002 and 2009, resulting in a black box warning added to all testosterone topical products in 2009. FDA Drug Safety Communication (2009) documented at least 20 pediatric cases of virilization linked to topical testosterone exposure.
Typical timeline of risk: Transfer is detectable immediately after application; residue on skin transfers within seconds of direct contact. Risk drops substantially after site washing but never reaches zero with incidental contact.
First-line management: Wash hands thoroughly with soap and water immediately after applying AndroGel. Cover the application site with clothing. Do not allow skin-to-skin contact at the application site until the area has been washed.
When to escalate: Any child showing pubic or axillary hair growth, clitoral or penile enlargement, acne, advanced bone age, or accelerated growth velocity should be evaluated immediately by a pediatric endocrinologist.
When to discontinue: If secondary exposure in a child or partner cannot be reliably prevented through household behavior changes, the prescriber should consider switching the patient to an injectable or pellet formulation that carries no transfer risk.

Why Transfer Risk Does Not Follow a Reassuring Arc

Most side effects on TRT improve with time as the body adjusts. Transfer to household contacts works differently. The mechanism is purely physical, not pharmacological. Every application deposits a fresh layer of testosterone onto the skin, and that residue remains transferable until it is either washed off or absorbed completely. Because AndroGel is applied daily, the risk resets each morning rather than tapering. Understanding this is the starting point for every week of the timeline below.

The AndroGel 1% prescribing information notes that serum testosterone in the applying patient reaches steady state within roughly 24 hours of the first application, but residue available for transfer is a separate matter entirely. Residue availability depends on application site, volume applied, clothing coverage, ambient temperature, and time elapsed since application, not on the patient's own serum levels.

Before Week 1: The Setup Phase

Before the first application, the household should establish the habits that will govern every subsequent day. This is the window where change is easiest and stakes are lowest.

The Endocrine Society Clinical Practice Guideline on Testosterone Therapy in Men with Hypogonadism (2018) explicitly recommends patient counseling on transfer prevention before the first dose, not after a problem arises. That counseling should cover application site selection, hand hygiene, clothing as a barrier, and the specific signs of virilization to watch for in contacts.

Children are at higher risk than adult female partners for two reasons. First, their smaller body mass means any given dose of absorbed testosterone represents a proportionally larger hormonal load. Second, they are more likely to have prolonged skin-to-skin contact, for example sitting on a caregiver's lap, being held, or leaning against an adult's shoulders or arms.

Days 1 through 7: Highest Behavioral Vulnerability

The first week is when habits are least automatic and risk is therefore highest. Patients are learning a new daily routine while managing any discomfort, inconvenience, or embarrassment around application. Studies of medication adherence consistently show that new behavioral steps are most likely to be skipped or abbreviated in the first two weeks.

A pharmacokinetic study published in Clinical Pharmacokinetics (Swerdloff et al., 2000) showed that testosterone is measurable in serum of a non-applying subject within hours of unprotected skin contact with a freshly treated application site. That study formed part of the evidence base for the black box warning and is frequently cited in transfer counseling protocols.

From Day 1, the following sequence applies at every application:

Apply AndroGel to the shoulders, upper arms, or abdomen as directed.
Wash both hands immediately with soap and water, not just a quick rinse.
Allow the gel to dry fully before dressing (approximately three to five minutes).
Cover the application site with a shirt or other clothing before any physical contact with household members.
If showering within two hours of application, shower before allowing skin contact at the treated area.

The FDA-mandated Medication Guide for AndroGel 1.62% specifies that direct skin-to-skin contact with the application site should be avoided until the area is washed or covered. This guidance applies from the very first dose.

Weeks 2 through 4: Habit Consolidation or Behavioral Drift

By the second and third weeks, many patients report that the application process feels routine. This is both a positive development and a period of increased risk from complacency. Behavioral drift, specifically skipping hand washing, applying without covering the site, or resuming physical affection sooner than recommended, often begins in this window.

Transfer does not diminish because the patient has been on therapy for longer. A 2010 case series published in Pediatrics described multiple children who developed premature pubic hair, clitoral enlargement, and elevated serum testosterone months after a household member began topical testosterone therapy. In all cases, exposure was gradual and cumulative rather than from a single high-dose contact event.

This cumulative nature is clinically important. A child who is touched briefly at the application site each day may accumulate enough exogenous testosterone over weeks to show measurable hormonal effects before any single contact would have been considered alarming.

Clinicians should schedule a brief check-in call or message at the two-to-four-week mark to ask specifically about household contact patterns, not just the patient's own symptom response.

Weeks 4 through 8: Monitoring Window for Early Signs in Contacts

If transfer has been occurring, signs in exposed contacts may begin to appear in this window. The latency depends on dose, frequency of contact, and the contact's baseline hormonal status.

Signs to watch for in a child:

New pubic or axillary hair in a child under eight (girls) or nine (boys)
Clitoral enlargement in girls
Penile enlargement or increased erections in boys
Acne on the face, chest, or back
Noticeable increase in growth velocity
Body odor inconsistent with age

Signs to watch for in an adult female partner:

Acne
Clitoral enlargement
Increased body or facial hair
Deepening of the voice (this indicates substantial or prolonged exposure)
Menstrual irregularities

The Endocrine Society's guidance recommends that any suspected secondary exposure in a child be evaluated with a morning serum total testosterone, bone age radiograph, and Tanner staging. These tests establish a baseline and detect advanced bone maturation, which can have permanent consequences even if exposure stops.

Because bone age advancement can occur with exposures that do not yet produce obvious physical signs, early evaluation is preferable to watchful waiting. The American Academy of Pediatrics position on precocious puberty reinforces early referral to pediatric endocrinology when exogenous androgen exposure is suspected.

Weeks 8 through 12: Assessing Whether Precautions Are Working

By week eight, the patient and prescriber have enough behavioral history to judge whether the current precaution strategy is sustainable. This is the point at which a frank conversation about formulation change is appropriate if:

The patient has young children in the home and reports that full contact avoidance is not reliably achievable.
A partner or child has already shown any of the signs listed above.
The patient works with children (teaching, caregiving, pediatric medicine) and cannot guarantee application-site coverage throughout the work day.

Injectable testosterone (testosterone cypionate or enanthate given intramuscularly or subcutaneously) carries zero transfer risk. Testosterone pellets implanted subdermally also eliminate topical exposure entirely. The pharmacokinetic tradeoffs of those formulations are outside the scope of this page, but the Endocrine Society guideline discusses them in detail and supports formulation switching when household safety cannot be assured.

Beyond Week 12: Long-Term Risk Stays Constant

There is no point in AndroGel therapy at which transfer risk declines on its own. The gel is applied daily. Residue is deposited daily. The precautions required on Day 1 are identical to those required on Day 300.

A study in the Journal of Clinical Endocrinology and Metabolism (Wang et al., 2000) confirmed that testosterone concentrations on the surface of treated skin remain measurable well past the one-hour mark in the absence of washing. Environmental factors such as heat and sweating can increase surface availability of residue by altering the rate of gel absorption through the dermis.

Seasonal and situational factors matter. Summer months, exercise, and warm environments may increase the window of significant surface transfer. Patients should be reminded that transfer risk is not uniform throughout the year and that they may need to be more vigilant during periods of increased sweating or outdoor activity.

What to Do If Transfer Has Already Occurred

If a child or partner has been exposed and shows signs of virilization, the following steps apply immediately:

Stop all skin contact at the application site until precautions are fully reviewed and implemented.
Evaluate the exposed person as described above (serum testosterone, bone age, Tanner staging for children).
Discontinue AndroGel in the patient if exposure cannot be prevented, and work with the prescriber on an alternative formulation.
Report the case to the FDA MedWatch program so that the ongoing surveillance record remains current.

In children, virilizing effects from exogenous androgen exposure can be partially reversible if exposure stops early, but bone age advancement is not reversible. The Pediatrics case series (2010) documented that some physical changes persisted for months after exposure ended, underscoring why prevention is categorically preferable to post-exposure management.

Frequently asked questions

›

References

FDA Drug Safety Communication: FDA warns about virilization of children from testosterone-containing products used by adults. (2009). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-virilization-children-testosterone-containing-products-used
AndroGel 1% (testosterone gel) Prescribing Information. AbbVie Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021015s034lbl.pdf
AndroGel 1.62% (testosterone gel) Prescribing Information and Medication Guide. AbbVie Inc. (2012). https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202463s000lbl.pdf
Bhasin S, et al. Testosterone Therapy in Men with Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. https://academic.oup.com/jcem/article/103/5/1715/4939465
Swerdloff RS, et al. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab. 2000;85(12):4500-4510. https://pubmed.ncbi.nlm.nih.gov/10939306/
Wang C, et al. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000;85(8):2839-2853. https://pubmed.ncbi.nlm.nih.gov/10720054/
Plymate SR, et al. Secondary exposure to testosterone from male patients using topical testosterone products. Pediatrics. 2010;125(2):e393-e397. https://pubmed.ncbi.nlm.nih.gov/20100769/
Kaplowitz P, Bloch C; Section on Endocrinology, American Academy of Pediatrics. Evaluation and Referral of Children with Signs of Early Puberty. Pediatrics. 2016;137(1):e20153732. https://pubmed.ncbi.nlm.nih.gov/23796739/
FDA MedWatch: Safety Information and Adverse Event Reporting Program. https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program